CSIMarket
 
Intermune Inc  (ITMN)
Other Ticker:  
 
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 99
 Employees -
 Revenues (TTM) (Millions $) 114
 Net Income (TTM) (Millions $) -236
 Cash Flow (TTM) (Millions $) 51
 Capital Exp. (TTM) (Millions $) 3

Intermune Inc
InterMune Inc. was a biotechnology company founded in 1998 and based in California, United States. The company focused on researching, developing, and commercializing therapies for the treatment of serious respiratory and orphan fibrotic diseases.

One of the key products developed by Intermune was Esbriet (pirfenidone), which was approved for the treatment of idiopathic pulmonary fibrosis (IPF) in several countries. IPF is a chronic and progressive lung disease that causes scarring of the lung tissue, leading to difficulty in breathing and reducing lung function. Esbriet helps to slow down the progression of IPF and improve lung function.

InterMune also conducted research into other potential therapies for diseases with high unmet medical needs, such as hepatitis C and nonalcoholic steatohepatitis (NASH). The company aimed to develop innovative treatments to address significant gaps in the current treatment options available for these diseases.

In 2014, Roche Holdings AG acquired Intermune Inc. for approximately $8.3 billion, gaining access to the company's portfolio of respiratory disease treatments. Following the acquisition, Intermune became a wholly-owned subsidiary of Roche and continued to operate under the Roche umbrella.

However, as of my last update in 2021, Intermune Inc. is no longer an independent company and its operations have been integrated into Roche's broader biopharmaceutical operations.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lifemd Inc

Healthcare Facilities company sees surge in revenue and reduction in deficit during recent fiscal period

Lifemd Inc, a renowned provider of virtual primary care services, has shown impressive growth in its most recent fiscal period. The company reported an energetic revenue rise of 64.276% to $45.50 million, which helped reduce losses to $-0.11 per share compared to $-0.36 per share in the corresponding reporting period a year ago. This significant improvement is a positive sign for investors and indicates that Lifemd Inc is on track to achieve profitability.
In contrast to the previous quarter, where revenue improved by 20.279% from $37.83 million, Lifemd Inc's income per share also witnessed improvement, increasing from $-0.20 per share. These positive developments highlight the company's strong performance and efficient cost management strategies.

Enhabit Inc

Enhabit Inc Reports $-0.13 per Share Deficit in Fiscal Fourth Quarter of 2023

Enhabit Inc, a home health and hospice care provider, has recently reported its financial results for the fiscal period ending in December 2023. The company recorded a loss of $-0.13 per share, compared to a loss of $-0.05 per share in the preceding reporting period. This represents a decrease in earnings from the same reporting period a year ago, where the company reported a loss of $-1.39 per share.
Despite the decrease in earnings per share, Enhabit Inc saw a slight increase in revenue of 0.89% from the previous reporting period, totaling $258.30 million. The company also reported a significant decrease in net deficit from $-68.000 million in the same reporting period a year ago to $-5.900 million in the current period.

Viemed Healthcare Inc

Viemed Healthcare Inc. Stuns Market with Impressive Earnings and Bold Strategic Move

Viemed Healthcare Inc's impressive earnings report and strategic decision to delist from the TSX in order to focus on growth on the NASDAQ Capital Market are certainly noteworthy developments in the stock market. The company's revenue and profit per share significantly outperformed its industry peers in the most recent fiscal period, indicating strong business performance and growth potential.
One key highlight from Viemed Healthcare's financial results is the significant increase in revenue and profit per share, showcasing the company's ability to drive top-line growth and improve profitability. Additionally, the company's improving profit margins and operating earnings demonstrate its operational efficiency and strategic management.

Progyny Inc

Serious headline: Progyny Inc. Reports Extraordinary Financial Performance in Q4 2023

Progyny Inc. has recently made headlines in the stock market with its impressive financial performance in the fourth quarter of 2023, showcasing substantial growth in both income per share and revenue. The company reported a significant increase in income per share by 339.82% year on year, soaring to $0.13 per share, and a revenue growth of 26.045% to $270.14 million. These numbers indicate a positive trajectory for the company, marking a notable improvement from the preceding period.
Furthermore, Progyny Inc. also reported a remarkable increase in net profits in the fourth quarter of 2023 earnings season, showing a staggering 295.25% growth from the same period a year ago. The company emphasized its improving profit margins, with net margin rising to 4.99% and operating margin edging up to 5.11%. Operating earnings also saw a substantial rise of 317.42% to $13.8 million.

Chemed Corporation

Chemed Corporation's Revenue Surges in Q4 2023, Setting the Stage for Future Growth



Chemed Corporation, a leading provider of end-of-life care and plumbing services, recently announced its financial results for the fourth quarter ended December 31, 2023. The company witnessed significant growth in its revenue, bottom-line earnings, and net income compared to the previous year. Chemed's improving profit margins and increasing demand signal positive prospects for the company's future. Additionally, the company's consistent dividend payments reflect its commitment to rewarding shareholders.
Financial Results Overview:
1. Revenue Growth:
In the fourth quarter of 2023, Chemed Corporation reported a revenue increase of 7.182% to $585.91 million, compared to $546.65 million in the previous year. This growth demonstrates the company's ability to generate higher sales in its healthcare facilities and plumbing services sectors.






 

Intermune Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com